DMDD & Mood Disorders – Quick Reference

Disruptive Mood Dysregulation Disorder (DMDD)

  • Definition: DMDD is a DSM-5-TR disorder with severe, chronic irritability, persistent negative mood (irritable, angry, or sad), and severe temper outbursts in children/adolescents; often misdiagnosed as bipolar disorder.
  • Diagnostic limits: should not be diagnosed in children < 66 years or adolescents > 1818 years.
  • Core features: chronic, nonepisodic irritability; outbursts disproportionate to the situation; outbursts typically due to frustration, manifested as exaggerated verbal rages or physical aggression; low frustration tolerance; poor emotion regulation and distress tolerance.
  • Behaviors: outbursts can be directed at property, self, or others; associated with severe impairment in childhood and adverse adolescent/adult outcomes.
  • Comorbidity and risk: high comorbidity with ODD, conduct disorder, ADHD, learning difficulties, depression; risk of antisocial personality disorder, substance use, and other psychiatric illness later in life.
  • Epidemiology: prevalence ranges between 2%−5%2\% - 5\%, more common among males and school-age children; seen in clinical settings.
  • Environmental influences: peer victimization and parenting significantly contribute to irritability; targeting triggers aids treatment.
  • Treatments (evidence-based within CB spectrum):
    • Social skills training;
    • Parent training;
    • Multisystemic therapy;
    • Exposure therapy (to increase frustration tolerance);
    • DBT-informed interventions with parent training.
  • Emerging approaches: environmental modification-based interventions; emphasize learning adaptive coping.
  • Notes: literature on DMDD is still developing; prevalence and guidelines continue to evolve.

Major Depressive Disorder (MDD) – Prevalence and Course

  • Global/US prevalence: approx 7%7\% of adults; about 17.3×10617.3 \times 10^6 people in the US; prevalence may be as high as 10%10\% depending on culture.
  • Severity: around 64%64\% report severe impairment among those with MDD.
  • Gender differences: higher prevalence in adult females across many populations.
  • Age distribution: most impacted group among adults is ages 18−2518-25 with about 13%13\% meeting criteria; lowest rates in those over 6565, though rates rise again after age 8585.
  • Course and prognosis: depression tends to be long-lasting and recurrent; untreated episodes often remit after 7−9 months7-9\text{ months}; relapse risk is high with about 75%75\% experiencing subsequent episodes after recovery; average across multiple episodes roughly four, with 14−17 weeks14-17\text{ weeks} per mild episode or 23 weeks23\text{ weeks} when severe.
  • Societal burden: loss of about 27 days27\text{ days} of work per year per affected individual; productivity costs around 37 billion37\text{ billion} annually.
  • Treatment implications: treatment improves recovery speed and reduces relapse risk; many delay seeking care due to barriers such as lack of insurance or stigma.
  • Pharmacotherapy: SSRIs are first-line for pediatric/adult depression; FDA black-box warning for suicidality on antidepressants; in youth, Prozac (fluoxetine) approved for ages 8+8+; Lexapro (escitalopram) approved for ages 12+12+; several SSRIs carry warnings; overall, untreated depression carries suicidality risk that treatment reduces.
  • Psychotherapy: CBT and interpersonal psychotherapy (IPT) effective in youth; combination of psychotherapy and medication recommended for many cases; ongoing suicidality monitoring is essential.
  • Pediatric focus: prevalence in youth shows age-specific patterns:
    • Preschoolers: MDD possible, but presentations include somatic complaints, irritability, anxiety, and behavior problems.
    • Children 6-11: incidence around 2%2\%; adolescence (12-17): up to 12%12\%; annual adolescent depressive episode prevalence ≈ 12.8%12.8\%.
    • Onset after puberty shows higher female prevalence; common comorbidities include ADHD, anxiety disorders, disruptive disorders, substance use, enuresis/encopresis, separation anxiety.
    • Outcomes: untreated pediatric depression linked to impaired school performance, interpersonal problems, and increased suicide risk; about 12%12\% of adolescents experience at least one major depressive episode; up to 8%8\% of adolescents with MDD complete suicide by young adulthood.
  • Early intervention: critical; psychotherapy (CBT/IPT) plus antidepressants is common; Prozac (fluoxetine) has strongest pediatric evidence among SSRIs.
  • Remission and relapse: most youth recover from a depressive episode, but future episodes are common; earlier onset, higher episode count, greater severity, and psychosocial stressors increase relapse risk.

Cultural Assets and Depression in Minorities

  • Environment and resilience: neighborhood, family dynamics, peer experiences, and group membership influence mental health and coping.
  • Resilience as protective factor: psychosocial resilience reduces risk of depressive disorders; resilience training proposed to enhance adaptation after adversity.
  • Racial/ethnic differences: prevalence and risk vary by group; some studies show lower MDD rates among Black and other minority groups, while risk patterns differ across regions and life stages.
  • Why this matters: treatment disparities persist for minorities; resilience mechanisms may operate differently across populations.
  • Comorbidity: MDD commonly co-occurs with anxiety disorders and PTSD.
  • Children and adolescents: depressive episodes affect roughly 3.1×1063.1\times 10^6 adolescents annually (~12.8%12.8\%); early onset and presentation differ from adults, leading to underrecognition and undertreatment.

Pediatric Depression and COVID-19

  • COVID-19 impact: disrupted routines and reduced access to routines like school, activities, and physical activity increase risk for anxiety/depression and social withdrawal.
  • Detection challenges: pandemic reduced opportunities for early mood disorder detection in youth; telehealth and screening efforts are critical.
  • Pediatric presentation: depression in preschoolers can resemble somatic and irritable symptoms; adolescents more closely align with DSM-5-TR criteria but still show unique patterns (e.g., weight/appetite changes, sleep disturbances).
  • Prevalence in youth: notable incidence rates in youth; early intervention with psychotherapy and SSRIs remains important.
  • Clinician considerations: monitor suicidality closely when starting antidepressants; ensure access to care during public health crises.

Characteristics of Bipolar Disorders – Mania and DSM-5-TR Criteria

  • Mood spectrum: mood disorders range from depression to mania; mania involves persistently elevated mood and heightened energy/goal-directed activity that disrupts functioning.
  • Bipolar spectrum: bipolar I, bipolar II, cyclothymic disorder, and rapid cycling bipolar disorder; all involve fluctuations between mood states and activity levels.
  • Mania overview: abnormally elevated/irritable mood with increased energy lasting at least 1 week1\text{ week} (or any duration if hospitalization is required).
  • DSM-5-TR criteria for a manic episode (A-D):
    • A: Distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased goal-directed activity or energy, lasting at least 1 week1\text{ week} and present most of the day.
    • B: During the period, three (or more) of the following symptoms (four if mood is only irritable) are present to a significant degree and represent a noticeable change from usual behavior:
    1. Inflated self-esteem or grandiosity
    2. Decreased need for sleep (e.g., feels rested after only 33 hours of sleep)
    3. More talkative than usual or pressure to keep talking
    4. Flight of ideas or subjective experience that thoughts are racing
    5. Distractibility (easy to draw to unimportant stimuli)
    6. Increase in goal-directed activity or psychomotor agitation
    7. Excessive involvement in high-risk activities
    • C: Mood disturbance causes marked impairment, or necessitates hospitalization, or there are psychotic features.
    • D: Episode not attributable to substances or another medical condition.
  • Lifetime criterion: at least one lifetime manic episode required for Bipolar I disorder.
  • Real-world example: Kanye West has exhibited manic symptoms (racing thoughts, sleep loss, paranoia, flight of ideas) while publicly discussing his diagnosis and treatment.
  • Functional risks: as mania intensifies, risk of impulsive behaviors (spending sprees, sexual indiscretions), disinhibited behavior, legal/financial problems, and potential hospitalization increase.
  • Important distinctions: mania can be highly functional temporarily but is inherently a mood disturbance with impairment.

Shades of Gray: Case Prompt – Carmen

  • Case prompt summarizes a college student with prolonged depressive symptoms, anhedonia, fatigue, weight loss, and recent suicidality.
  • Based on timeframe and symptom profile, the likely diagnosis would be Major Depressive Disorder (MDD) given persistent mood disturbance and functional impairment described. (Discussion area noted in chapter.)